News | March 06, 2026
Alembic enters US branded market with first sales of Pivya UTI treatment
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Subscribe To Our Newsletter & Stay Updated
